Related Experiment Videos
Stable expression of recombinant factor VIII molecules using a bovine papillomavirus vector
1Molecular Biology Division, Rorer Biotechnology Inc., Springfield, VA 22151.
DNA (Mary Ann Liebert, Inc.)
|December 1, 1987
Summary
Scientists engineered cells to produce Factor VIII (FVIII), a protein crucial for blood clotting. A modified FVIII lacking a specific domain showed significantly higher coagulant activity, suggesting improved therapeutic potential for hemophilia A.
Area of Science:
- Biochemistry
- Molecular Biology
- Hematology
Background:
- Hemophilia A is a bleeding disorder caused by Factor VIII (FVIII) deficiency.
- FVIII is a large glycoprotein essential for blood coagulation.
- FVIII activation involves proteolytic cleavage and removal of its B domain.
Purpose of the Study:
- To create genetically engineered cell lines expressing full-length and B domain-deleted FVIII.
- To compare the biological activity of recombinant full-length FVIII and delta FVIII.
- To investigate the efficiency of coagulant activity expression.
Main Methods:
- Utilized a bovine papillomavirus expression vector system.
- Established stable cell lines harboring full-length FVIII cDNA or variant delta FVIII cDNA.
- Assessed biological attributes and coagulant activity of expressed FVIII molecules.
Main Results:
- Both recombinant FVIII molecules exhibited biological attributes of native FVIII.
- Cells expressing delta FVIII cDNA showed 5-8 times greater coagulant activity than full-length FVIII transformants.
- The enhanced expression efficiency of delta FVIII is attributed to a post-transcriptional event.
Conclusions:
- A B domain-deleted FVIII variant can be efficiently expressed in genetically engineered cells.
- This delta FVIII demonstrates superior coagulant activity compared to full-length FVIII.
- The findings suggest potential for improved recombinant FVIII therapies for hemophilia A.